Gain Therapeutics, Inc. (GANX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Gain Therapeutics, Inc. (GANX) closed at USD 1.32 on 2026-10-14, a change of -31.2 % over the past year, with a market capitalization of USD 58.05M.

Gain Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Gain Therapeutics, Inc. key figures

Previous close

USD 1.32 (2026-10-14)

1-year change

-31.2 %

Market cap

USD 58.05M

Enterprise value

USD 45.57M

P/E ratio (trailing)

-2.83

P/E ratio (forward)

-1.94

EPS (trailing)

-0.47

EPS (forward)

-0.69

PEG ratio

n/a

Price to book

5.10

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.27

Employees

20

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Gain Therapeutics, Inc. and compare it with other stocks.